SETTING: Patients with cavitary pulmonary tuberculosis (TB) on baseline chest radiograph (CXR) who remain culture-positive after 8 weeks of treatment are at high risk of relapse. The role of end-of-treatment (EOT) CXR in predicting relapse is unclear. OBJECTIVE: To determine whether EOT CXR independently predicts TB relapse. DESIGN: We conducted a secondary analysis of a randomized trial of intermittent treatment using rifapentine in the continuation phase of TB treatment among 1004 human immunodeficiency virus seronegative adults with culture-proven pulmonary TB. RESULTS:Relapse occurred in 17.3% of subjects with persistent cavity on EOT CXR, in 7.6% of subjects with a cavity that resolved by EOT, and 2.5% (P=0.002 for trend) of subjects who never had a cavity. In multivariable analysis, patients with persistent cavity on EOT CXR were significantly more likely to relapse than patients with no cavity on baseline or 2-month CXR (hazard ratio [HR] 4.22, 95%CI 2.00-8.91), and were more likely to relapse than subjects whose early cavity had resolved by EOT CXR (HR 1.92, 95%CI 1.09-3.39). CONCLUSION: A persistent cavity after 6 months of TB treatment was independently associated with disease relapse after controlling for other variables. EOT CXR may help predict those likely to relapse.
RCT Entities:
SETTING:Patients with cavitary pulmonary tuberculosis (TB) on baseline chest radiograph (CXR) who remain culture-positive after 8 weeks of treatment are at high risk of relapse. The role of end-of-treatment (EOT) CXR in predicting relapse is unclear. OBJECTIVE: To determine whether EOT CXR independently predicts TB relapse. DESIGN: We conducted a secondary analysis of a randomized trial of intermittent treatment using rifapentine in the continuation phase of TB treatment among 1004 human immunodeficiency virus seronegative adults with culture-proven pulmonary TB. RESULTS: Relapse occurred in 17.3% of subjects with persistent cavity on EOT CXR, in 7.6% of subjects with a cavity that resolved by EOT, and 2.5% (P=0.002 for trend) of subjects who never had a cavity. In multivariable analysis, patients with persistent cavity on EOT CXR were significantly more likely to relapse than patients with no cavity on baseline or 2-month CXR (hazard ratio [HR] 4.22, 95%CI 2.00-8.91), and were more likely to relapse than subjects whose early cavity had resolved by EOT CXR (HR 1.92, 95%CI 1.09-3.39). CONCLUSION: A persistent cavity after 6 months of TB treatment was independently associated with disease relapse after controlling for other variables. EOT CXR may help predict those likely to relapse.
Authors: H T W Quy; N T N Lan; M W Borgdorff; J Grosset; P D Linh; L B Tung; D van Soolingen; M Raviglione; N V Cô; J Broekmans Journal: Int J Tuberc Lung Dis Date: 2003-07 Impact factor: 2.373
Authors: S Graham; Gupta K Das; R J Hidvegi; R Hanson; J Kosiuk; Zahrani K Al; D Menzies Journal: Int J Tuberc Lung Dis Date: 2002-02 Impact factor: 2.373
Authors: Debra Benator; Mondira Bhattacharya; Lorna Bozeman; William Burman; Antonino Cantazaro; Richard Chaisson; Fred Gordin; C Robert Horsburgh; James Horton; Awal Khan; Christopher Lahart; Beverly Metchock; Constance Pachucki; Llewellyn Stanton; Andrew Vernon; M Elsa Villarino; Yong Chen Wang; Marc Weiner; Stephen Weis Journal: Lancet Date: 2002-08-17 Impact factor: 79.321
Authors: Elizabeth L Corbett; Salome Charalambous; Katherine Fielding; Tim Clayton; Richard J Hayes; Kevin M De Cock; Gavin J Churchyard Journal: J Infect Dis Date: 2003-10-03 Impact factor: 5.226
Authors: Thomas R Frieden; Timothy R Sterling; Sonal S Munsiff; Catherine J Watt; Christopher Dye Journal: Lancet Date: 2003-09-13 Impact factor: 79.321
Authors: Richard E Nettles; Dana Mazo; Karla Alwood; Regina Gachuhi; Gina Maltas; Karen Wendel; Wendy Cronin; Nancy Hooper; William Bishai; Timothy R Sterling Journal: Clin Infect Dis Date: 2004-02-17 Impact factor: 9.079
Authors: Heather M Kling; Gerard J Nau; Ted M Ross; Thomas G Evans; Krishnendu Chakraborty; Kerry M Empey; JoAnne L Flynn Journal: Ann Am Thorac Soc Date: 2014-08
Authors: Laura E Via; Dan Schimel; Danielle M Weiner; Veronique Dartois; Emmanuel Dayao; Ying Cai; Young-Soon Yoon; Matthew R Dreher; Robin J Kastenmayer; Charles M Laymon; J Eoin Carny; Joanne L Flynn; Peter Herscovitch; Clifton E Barry Journal: Antimicrob Agents Chemother Date: 2012-06-11 Impact factor: 5.191
Authors: Philana Ling Lin; Teresa Coleman; Jonathan P J Carney; Brian J Lopresti; Jaime Tomko; Dan Fillmore; Veronique Dartois; Charles Scanga; L James Frye; Christopher Janssen; Edwin Klein; Clifton E Barry; JoAnne L Flynn Journal: Antimicrob Agents Chemother Date: 2013-06-24 Impact factor: 5.191
Authors: Russell R Kempker; Aline B Barth; Sergo Vashakidze; Ketino Nikolaishvili; Irina Sabulua; Nestani Tukvadze; Nino Bablishvili; Shota Gogishvili; Ravi Shankar P Singh; Jeannette Guarner; Hartmut Derendorf; Charles A Peloquin; Henry M Blumberg Journal: Antimicrob Agents Chemother Date: 2015-03-16 Impact factor: 5.191
Authors: Laura E Via; Danielle M Weiner; Daniel Schimel; Philana Ling Lin; Emmanuel Dayao; Sarah L Tankersley; Ying Cai; M Teresa Coleman; Jaime Tomko; Praveen Paripati; Marlene Orandle; Robin J Kastenmayer; Michael Tartakovsky; Alexander Rosenthal; Damien Portevin; Seok Yong Eum; Saher Lahouar; Sebastien Gagneux; Douglas B Young; Joanne L Flynn; Clifton E Barry Journal: Infect Immun Date: 2013-05-28 Impact factor: 3.441
Authors: Michael E Urbanowski; Alvaro A Ordonez; Camilo A Ruiz-Bedoya; Sanjay K Jain; William R Bishai Journal: Lancet Infect Dis Date: 2020-05-05 Impact factor: 25.071